Alkermes plc (NASDAQ:ALKS) Stock Position Lifted by US Bancorp DE

US Bancorp DE lifted its position in Alkermes plc (NASDAQ:ALKS) by 48.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,302 shares of the company’s stock after acquiring an additional 3,378 shares during the quarter. US Bancorp DE’s holdings in Alkermes were worth $288,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in ALKS. V Square Quantitative Management LLC bought a new stake in Alkermes during the third quarter valued at $29,000. Signaturefd LLC grew its position in shares of Alkermes by 51.2% during the 2nd quarter. Signaturefd LLC now owns 1,417 shares of the company’s stock valued at $34,000 after buying an additional 480 shares during the last quarter. Hexagon Capital Partners LLC raised its stake in Alkermes by 3,841.0% during the second quarter. Hexagon Capital Partners LLC now owns 1,537 shares of the company’s stock worth $37,000 after acquiring an additional 1,498 shares during the period. GAMMA Investing LLC lifted its holdings in Alkermes by 44.4% in the second quarter. GAMMA Investing LLC now owns 2,287 shares of the company’s stock worth $55,000 after acquiring an additional 703 shares during the last quarter. Finally, Ashton Thomas Private Wealth LLC acquired a new position in Alkermes in the second quarter valued at approximately $116,000. 95.21% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Stifel Nicolaus raised Alkermes from a “hold” rating to a “buy” rating and raised their price target for the stock from $25.00 to $36.00 in a report on Tuesday, November 5th. JPMorgan Chase & Co. reduced their price target on shares of Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Robert W. Baird upped their price target on shares of Alkermes from $37.00 to $38.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Cantor Fitzgerald cut their price objective on shares of Alkermes from $48.00 to $43.00 and set an “overweight” rating on the stock in a research report on Friday, October 25th. Finally, Mizuho upped their target price on shares of Alkermes from $35.00 to $40.00 and gave the stock an “outperform” rating in a research report on Wednesday. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $35.42.

Alkermes Trading Up 0.0 %

NASDAQ:ALKS opened at $29.24 on Thursday. The stock has a fifty day simple moving average of $27.71 and a 200 day simple moving average of $26.16. The firm has a market capitalization of $4.73 billion, a price-to-earnings ratio of 14.94, a price-to-earnings-growth ratio of 0.98 and a beta of 0.47. Alkermes plc has a 1-year low of $22.06 and a 1-year high of $32.88. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22.

Insider Activity

In other news, EVP Craig C. Hopkinson sold 58,996 shares of Alkermes stock in a transaction on Monday, November 11th. The stock was sold at an average price of $30.08, for a total transaction of $1,774,599.68. Following the transaction, the executive vice president now owns 83,300 shares in the company, valued at approximately $2,505,664. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, EVP Craig C. Hopkinson sold 10,471 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $29.53, for a total value of $309,208.63. Following the transaction, the executive vice president now owns 99,238 shares in the company, valued at approximately $2,930,498.14. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Craig C. Hopkinson sold 58,996 shares of Alkermes stock in a transaction on Monday, November 11th. The shares were sold at an average price of $30.08, for a total transaction of $1,774,599.68. Following the completion of the sale, the executive vice president now directly owns 83,300 shares of the company’s stock, valued at approximately $2,505,664. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.89% of the company’s stock.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.